Department of Radiology, Neuroradiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Via Aldo Moro, 44124 Ferrara, Italy.
Department of Neuroradiology, Ospedale Bellaria, IRCCS Institute of Neurological Sciences of Bologna, Via Altura, 3; 40100 Bolgona, Italy.
Br J Radiol. 2020 Sep 1;93(1113):20200321. doi: 10.1259/bjr.20200321. Epub 2020 Jul 6.
Pituitary macroadenomas (PAs) are usually defined as benign intracranial tumors. However, they may present local aggressive course. High Ki67 labelling index (LI) values have been related to an aggressive tumor behavior. A recent clinicopathological classification of PA based on local invasiveness and proliferation indexes, divided them in groups with different prognosis. We evaluated the utility of conventional MRI (cMRI) and diffusion-weighted imaging (DWI), in predicting the Ki67- LI according the clinicopathological classification.
17 patients (12 M and 5 F) who underwent surgical removal of a PA were studied. cMRI features, quantification of W and W signal intensity, degree of contrast uptake (enhancement ratio, ER) and apparent diffusion coefficient (ADC) values were evaluated by using a 3 T scan. Statistics included Mann-Whitney test, Spearman's test, and receiver operating characteristic analysis. A value of ≤ 0.05 was considered significant for all the tests.
Negative correlations were observed between Ki-67 LI, ADCm (ρ = - 0.67, value = 0.005) and ER values (ρ = -0.62; = 0.008). ER values were significantly lower in the proliferative PA group ( = 0.028; = 0.017). ADCm showed sensitivity and specificity of 90 and 85% respectively into predict Ki67-LI value. A value of ADCm ≤0, 711 x 10-6 mm emerged as a cut-off of a value of Ki67-LI ≥ 3%.
Adding quantitative measures of ADC values to cMRI could be used routinely as a non-invasive marker of specific predictive biomarker of the proliferative activity of PA.
Routinely use of DWI on diagnostic work-up of pituitary adenomas may help in establish the likely biological aggressive lesions.
垂体大腺瘤(PA)通常被定义为良性颅内肿瘤。然而,它们可能表现出局部侵袭性病程。高 Ki67 标记指数(LI)值与侵袭性肿瘤行为相关。最近基于局部侵袭性和增殖指数的 PA 临床病理分类,将它们分为具有不同预后的组。我们评估了常规 MRI(cMRI)和弥散加权成像(DWI)在预测根据临床病理分类的 Ki67-LI 中的效用。
研究了 17 例(12 例男性和 5 例女性)接受手术切除 PA 的患者。通过 3 T 扫描评估 cMRI 特征、W 和 W 信号强度的定量、对比摄取程度(增强比,ER)和表观弥散系数(ADC)值。统计分析包括曼-惠特尼检验、斯皮尔曼检验和受试者工作特征分析。所有检验均以 值≤0.05 为显著。
Ki-67 LI 与 ADCm(ρ=-0.67, 值=0.005)和 ER 值(ρ=-0.62; 值=0.008)呈负相关。增殖性 PA 组的 ER 值明显较低( =0.028; 值=0.017)。ADCm 对预测 Ki67-LI 值的灵敏度和特异性分别为 90%和 85%。ADCm 值≤0.711 x 10-6 mm 作为 Ki67-LI 值≥3%的截断值。
在 cMRI 中添加 ADC 值的定量测量值可常规用作预测 PA 增殖活性的特定预测生物标志物的非侵入性标志物。
在垂体腺瘤的诊断工作中常规使用 DWI 可能有助于确定可能的生物学侵袭性病变。